1AI
Algorae Pharmaceuticals Ltd
Director Trades
| Date | Director | Value |
|---|
Company News
Algorae Pharmaceuticals Achieves Independent Validation of AlgoraeOS and Launches Enhanced v2 Platform
Algorae Pharmaceuticals (ASX: 1AI) has reported independent preclinical validation of its AlgoraeOS v1 drug-combination prediction platform following a major study at the Victorian Centre for Functional Genomics at the Peter MacCallum Cancer Centre.
Algorae Pharmaceuticals to Partner with Dr Reddy’s for Australian Supply of Chemotherapy Medicine
Algorae Pharmaceuticals (ASX: 1AI) has signed a distribution partnership with Indian multinational Dr Reddy’s Laboratories to supply chemotherapy medicine capecitabine to the Australian market.
Algorae Pharmaceuticals Launches Upgraded Version of AlgoraeOS Drug Discovery Platform
Algorae Pharmaceuticals (ASX: 1AI), in collaboration with the UNSW and CSIRO, has launched a major upgrade to its AlgoraeOS AI-driven platform for the discovery of drug combinations.
Algorae Pharmaceuticals Driving Expansion with Innovation and Commercialisation
Algorae Pharmaceuticals (ASX: 1AI) has reported a period of significant expansion as it broadens its operations to include complementary commercial activities. In the three months to end September, the company advanced its dual-track strategy of AI-driven innovation and pharmaceutical commercialisation, securing two landmark deals to expand its presence across Australia and New Zealand. Algorae also advanced […]
Algorae Pharmaceuticals Expands Commercial Footprint with New Cadila Partnership
Algorae Pharmaceuticals (ASX: 1AI) and private Indian company Cadila Pharmaceuticals have entered into a licence and supply agreement covering two new generic medicines for the Australian and New Zealand markets. The agreement will formalise an operational framework for the partnership and will see Algorae commence planning for Therapeutic Goods Administration (TGA) registration to enable commercialisation of […]
Algorae Pharmaceuticals to Launch Five New Oncology Medicines in Australia-New Zealand Markets
Algorae Pharmaceuticals (ASX: 1AI) has entered into an exclusive licencing agreement with Indian pharmaceutical manufacturer Sakar Healthcare to launch five generic oncology medicines into the Australian and New Zealand markets. The products will be marketed under the Algorae brand to meet the needs of the combined market, which analysts value at approximately $10 million per […]
Algorae Pharmaceuticals Advances Validation for Oncology-Focused Predictive Drug Combinations
Algorae Pharmaceuticals (ASX: 1AI) achieved a key milestone in the recent June quarter, locking in a strategic partnership with the Victorian Centre for Functional Genomics (VCFG) at Melbourne’s Peter MacCallum Cancer Centre. The partners are working on high-throughput experimental validation for 21 in silico predictions generated by the AI-enabled AlgoraeOS Version 1.0, alongside three drug […]
Algorae Pharmaceuticals teams with Peter MacCallum Centre to validate AI-predicted cancer drug synergies
Algorae Pharmaceuticals (ASX: 1AI) has partnered with the Victorian Centre for Functional Genomics (VCFG) at the Peter MacCallum Cancer Centre in Melbourne to validate AI-predicted drug synergies using high-throughput screening. The companies will conduct a study to confirm the efficacy of drug combinations and dose ranges across four distinct cancer cell lines including glioblastoma, pancreatic […]
Algorae Pharmaceuticals strengthens drug pipeline as AlgoraeOS Version 2.0 development continues
Algorae Pharmaceuticals (ASX: 1AI) has reported continued advancements to its proprietary Algorae Operating System (or AlgoraeOS) artificial intelligence (AI) drug discovery platform since it was officially launched in September. The AI-driven innovation has identified 24 novel drug targets in the past seven months, focusing on high-impact oncology indications such as breast cancer, leukaemia and glioblastoma. […]
Algorae Pharmaceuticals strengthens leadership team with appointment of new chief commercial officer
Algorae Pharmaceuticals (ASX: 1AI) has strengthened its leadership team with the appointment of seasoned pharmaceutical executive Vishal Shah to the role of chief commercial officer. Mr Shah has over 20 years’ experience in the pharmaceuticals, biotechnology and healthcare industries. He will spearhead Algorae’s commercial strategy to accelerate growth and expansion into complementary pharmaceutical market segments. […]
Company Videos
No videos found.